References

1. Starzl TE: Discussion of Murray JE, Wilson RE, Tilney NL, et al. Five years experience in renal transplantation with immunosuppressive drugs: survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 168:416, 1968.

2. Geis WP, Iwatsuki S, Molnar Z, et al.: Pseudolymphoma in renal allograft recipients. Arch Surg 113:461, 1978.

3. Paya CV, Fung JJ, Nalesnik MA, et al.: Epstein-Barr virus-induced post transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517-1525, 1999.

4. Gross TG, Steinbuch M, DeFor T, et al.: B cell lympho-proliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 23:251-258, 1999.

5. Chen JM, Barr ML, Chadburn A, et al.: Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 56:527, 1993.

6. Raymond E, Tricottet V, Samuel D, Reynes M, Bismuth H, Misset JL: Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Cancer 76:1344, 1995.

7. Montone KT, Litzky LA, Wurster A, et al.: Analysis of Epstein-Barr virus-associated posttransplantation lym-phoproliferative disorder after lung transplantation. Surgery 119: 544, 1996.

8. Micallef IN, Chhanabhai M, Gascoyne RD, et al.: Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 22(10):981-987, 1998 Nov.

responders: 8 of 14 patients achieved a CR.60 Patients treated with IFN-a in various studies have received additional therapies, and this makes it unclear whether IFN-a is truly an effective therapy for PTLD.11 The toxicity and lower response rates associated with IFN-a also makes it less appealing than more recent options such as rituximab.

0 0

Post a comment